Evaluating cost benefits of combination therapies for advanced melanoma

Evaluating cost benefits of combination therapies for advanced melanoma

Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 months. Recently, combination targeted therapies have i...

Full description

Bibliographic Details
Main Authors:	Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2016-07-01
Series:	Drugs in Context
Subjects:	metastatic melanoma BRAF V600E mutation-positive cost-benefit model targeted therapy immunotherapy dabrafenib trametinib combination therapy
Online Access:	http://www.drugsincontext.com/evaluating-cost-benefits-of-combination-therapies-for-advanced-melanoma/

Similar Items

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
by: Lili Mao, et al.
Published: (2021-08-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
by: Victoria G. Atkinson, et al.
Published: (2021-05-01)

Anaplastic thyroid cancer. Is there a light at the end of the tunnel?
by: A. L. Pylev, et al.
Published: (2020-04-01)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi M, et al.
Published: (2016-05-01)

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
by: Andrea Boutros, et al.
Published: (2020-11-01)

[Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market]
by: Lorenzo Pradelli, et al.
Published: (2016-12-01)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
by: Marilda Mormando, et al.
Published: (2020-07-01)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <i>BRAF</i> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
by: Jean-Bernard Auliac, et al.
Published: (2020-12-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
by: Adil Daud, et al.
Published: (2017-01-01)

Uveitis as a Result of MAP Kinase Pathway Inhibition
by: Lavnish Joshi, et al.
Published: (2013-11-01)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
by: Tran KA, et al.
Published: (2015-12-01)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
by: Yuta Adachi, et al.
Published: (2020-02-01)

BRAF Gene and Melanoma: Back to the Future
by: Margaret Ottaviano, et al.
Published: (2021-03-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
by: Orion Valet, et al.
Published: (2021-06-01)

BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
by: Ivana Inić, et al.
Published: (2014-09-01)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF<sup><it>V600D/R</it></sup> mutations
by: Gentilcore Giusy, et al.
Published: (2013-01-01)

NRAS-mutant melanoma: current challenges and future prospect
by: Muñoz-Couselo E, et al.
Published: (2017-08-01)

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
by: Jan Dörrie, et al.
Published: (2018-01-01)

FAST-GROWING MALIGNANT MELANOMA
by: Florica Sandru, et al.
Published: (2019-12-01)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
by: Long Yuan, et al.
Published: (2020-06-01)

Current State of Target Treatment in BRAF Mutated Melanoma
by: Enrica Teresa Tanda, et al.
Published: (2020-07-01)

Molecular background of skin melanoma development and progression: therapeutic implications
by: Magdalena Olbryt
Published: (2019-05-01)

Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing?
by: Victoria Grätz, et al.
Published: (2019-12-01)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
by: Tianfu Gao, et al.
Published: (2021-06-01)

Targeted Therapies for Melanoma
by: Karel Smetana, et al.
Published: (2020-09-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
by: Yu Z, et al.
Published: (2018-12-01)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

Modern options in personalized therapy of metastatic cutaneous melanoma
by: S A Protsenko, et al.
Published: (2014-09-01)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
by: Huan Yu, et al.
Published: (2017-12-01)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
by: Valpione Sara, et al.
Published: (2015-03-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
by: Francesco Serra, et al.
Published: (2021-08-01)

Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)

Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report
by: Stefano Cavalieri, et al.
Published: (2017-07-01)